Survivor function adjusted for concomitant TB therapy.

<p>Survivor function adjusted for concomitant TB therapy.</p

Baseline characteristics.

<p>Baseline characteristics.</p

Management of ICU patients with PCP.

<p>Management of ICU patients with PCP.</p

Consort diagram.

<p>* Criteria for screening records included: any positive test result, all patients with negative results from ICUs and high care units, laboratory request forms listing HIV infection or suspected PCP.</p

Additional file 1: Table S1. of Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis

Full search strategy. (PDF 817 kb

Additional file 3: of Burden of pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis

Summary table of included study cohorts. (DOCX 158 kb

Clinical appearance of skin lesions after treatment with amphotericin B followed by itraconazole and concomitant prednisone tapered over three months.

<p>Clinical appearance of skin lesions after treatment with amphotericin B followed by itraconazole and concomitant prednisone tapered over three months.</p

Clinicopathological features of a patient with HIV-associated emergomycosis initially and following antiretroviral-mediated immune reconstitution.

<p>(A) Clinical appearance of skin lesions at first biopsy. (B, C) High-power magnification histology of first skin punch biopsy showing (B) scanty macrophages and apoptotic nuclear debris around superficial dermal vessels (haematoxylin and eosin stain, x400) and (C) numerous small budding yeasts (Grocott methenamine silver stain, x400). (D) Clinical appearance at the time of second biopsy five months after the first. (E, F) High-power magnification histology of second skin punch biopsy showing (E) replacement of the entire dermis by dense sheets of foamy macrophages and admixed lymphocytes (haematoxylin and eosin stain, x400) and (F) isolated yeast-like structures (arrows; Periodic acid-Schiff stain, x400).</p

Additional file 1 of Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial

Additional file 1. Modified MARAIS Score (modified from Marais et al. [27])

Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.

OBJECTIVE: We aimed to compare clinical severity of Omicron BA.4/BA.5 infection with BA.1 and earlier variant infections among laboratory-confirmed SARS-CoV-2 cases in the Western Cape, South Africa, using timing of infection to infer the lineage/variant causing infection. METHODS: We included public sector patients aged ≥20 years with laboratory-confirmed COVID-19 between 1-21 May 2022 (BA.4/BA.5 wave) and equivalent prior wave periods. We compared the risk between waves of (i) death and (ii) severe hospitalization/death (all within 21 days of diagnosis) using Cox regression adjusted for demographics, comorbidities, admission pressure, vaccination and prior infection. RESULTS: Among 3,793 patients from the BA.4/BA.5 wave and 190,836 patients from previous waves the risk of severe hospitalization/death was similar in the BA.4/BA.5 and BA.1 waves (adjusted hazard ratio (aHR) 1.12; 95% confidence interval (CI) 0.93; 1.34). Both Omicron waves had lower risk of severe outcomes than previous waves. Prior infection (aHR 0.29, 95% CI 0.24; 0.36) and vaccination (aHR 0.17; 95% CI 0.07; 0.40 for at least 3 doses vs. no vaccine) were protective. CONCLUSION: Disease severity was similar amongst diagnosed COVID-19 cases in the BA.4/BA.5 and BA.1 periods in the context of growing immunity against SARS-CoV-2 due to prior infection and vaccination, both of which were strongly protective